Presented by Robert W. Carlson, MD, NCCN, Fort Washington, Pennsylvania, and Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Natl Compr Canc Netw. 2016 May;14(5 Suppl):616-9. doi: 10.6004/jnccn.2016.0177.
NCCN has developed a series of Evidence Blocks: graphics that provide ratings for each recommended treatment regimen in terms of efficacy, toxicity, quality and consistency of the supporting data, and affordability. The NCCN Evidence Blocks are currently available in 10 tumor types within the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). At a glance, patients and providers can understand how a given treatment was assessed by the NCCN Guidelines Panel and get a sense of how a given treatment may match individual needs and preferences. Robert W. Carlson, MD, CEO of NCCN, described the reasoning behind this new feature and how the tool is used, and Eric Jonasch, MD, Professor of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, and Vice Chair of the NCCN Kidney Cancer Panel, described its applicability in the management of metastatic renal cell carcinoma.
NCCN 制定了一系列证据块:图形,根据疗效、毒性、数据支持的质量和一致性以及可负担性,对每个推荐的治疗方案进行评级。NCCN 证据块目前可用于 NCCN 肿瘤学临床实践指南(NCCN 指南)中的 10 种肿瘤类型。患者和提供者可以一目了然地了解 NCCN 指南专家组如何评估给定的治疗方法,并了解给定的治疗方法如何符合个人的需求和偏好。NCCN 的首席执行官 Robert W. Carlson, MD 描述了这一新功能的背后逻辑以及该工具的使用方式,德克萨斯大学 MD 安德森癌症中心泌尿生殖系统医学肿瘤学教授、NCCN 肾癌专家组副主席 Eric Jonasch, MD 描述了其在转移性肾细胞癌管理中的适用性。